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The controversial, but later widely celebrated, World Bank Report of 1993, Investing in Health, moved finance ministers all over the world to reconsider insufficient 
funding for health in low- and middle-income countries (1,2).
Global Health Initiatives, such as the Global Fund to Fight 
AIDS, Tuberculosis and Malaria; and the Global Alliance for 
Vaccines and Immunization (GAVI) were launched in the same 
spirit: investing in health is necessary, a moral imperative, and 
if done wisely it will provide large economic returns (3). When 
Bill Gates moved into philanthropy, the report that inspired 
him most was World Development Report (WDR) 1993 (4). 
When the former Norwegian Prime Minister Jens Stoltenberg 
announced the first billion for GAVI (together with Gates), he 
referred to the substantial returns from investing in vaccines 
(5)—a “drop of gold”, as they were called in The Economist (6). 
When Gro Harlem Brundtland became the Director General of 
the World Health Organization  (WHO) in 1998, the first thing 
she did was to call upon Jeffrey Sachs to summarize evidence 
about the macro-economic benefits of improving health (7). 
She also endorsed the second main message of WDR 1993—
priority setting according to cost-effectiveness. She saw priority 
setting as a means to move toward universal health coverage: “if 
services are to be provided for all, then not all services can be 
provided. The most cost-effective services should be provided 
first” (8). 
The last decade in global health has been characterized by 
optimism (9). The number of child deaths dropped from 11.9 
million deaths in 1990 to 7.7 million deaths in 2010, a more 
rapid decline than ever expected (10). More people are sleeping 
under insecticide-treated mosquito nets than ever, and more 
people have access to Antiretroviral Therapies (ARTs) than 
anyone hoped for when UNAIDS, WHO, and others in 2003 
launched the “3 by 5” initiative. In 2012, more than 9.7 million 
people living with HIV were receiving ARTs in low- and 
middle-income countries (11). If we look at the overall health 
outcomes, life expectancy in low-income countries increased 
with six years for males and females from the year 2000 to 2011 
(12). That is more than half a year average health improvement 
in the worst-off populations every year since 2000. 
The challenge
And yet, starting with the financial crisis in 2008, Development 
Assistance for Health (DAH) has flattened out, countries are 
told to increase their own funding for antiretrovirals for HIV, 
and there are still vast inequalities in mortality and morbidity 
(13). Many countries are afraid that they will be left behind. The 
burden of disease is substantial, with many countries undergoing 
a demographic transition so that they now experience a double 
or even a triple burden: the high burden from communicable 
diseases, the emerging chronic diseases, and the persistent high 
numbers of healthy life years lost from injuries (14). Access to 
a wide range of modern health services, such as prevention and 
treatment for cardiovascular disease and cancer, is only available 
for those who can afford them (15). Universal health coverage 
is, but a distant dream. The unfinished agenda is still with us. 
The grand global challenge is still inequality in mortality and 
life expectancy, between countries and within countries. The 
difference in life expectancy at birth between high- and low-
income countries was 20 years in 2011; 60.2 in low-income 
countries and 80.2 in high-income countries (12). Within 
countries, such as in Ethiopia—one of the African countries 
with the largest economic growth, but still one of the poorest 
countries in the world—the estimated difference between the 
poorest and the not so poor upper quintile was nine years in 
2011 (16). If we apply another inequality measure—Absolute 
Length of life Inequality (ALI): the average difference in life 
expectancy between two randomly picked individuals in a 
population—the difference was 27.6 years in Ethiopia in 2011 
(16). Some live long and healthy lives, but too many have their 
lives cut short prematurely. 
And yet, change is possible. A new optimism is justified. 
According to Global Health 2035, the Lancet Commission 
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celebrating the 20th anniversary of the WDR 1993, the world 
now has the unique opportunity to achieve a grand convergence 
in global mortality within a generation. 
Investing in health
Global Health 2035 is an ambitious new investment framework 
to begin closing this health gap. Written by a group of economists 
and global health experts, Global Health 2035 argues that a 
convergence is possible for infectious, child, and maternal 
mortality. Major reductions in the incidence and consequences 
of Non-Communicable Diseases (NCDs) are also within reach. 
Their findings can be summarized in four key points:
 
1. A “grand convergence” in health is achievable within our 
lifetimes
Countries can learn from middle-income countries that 
have made wise investments in health. The report points to 
the “4C countries”—Chile, China, Costa Rica, and Cuba—
which started off at similar levels of income and mortality as 
today’s low-income countries. They are now among the best-
performing middle-income countries. Low-income countries 
can, and should, scale up existing (and new) interventions 
targeting reproductive, maternal, neonatal, and child health 
conditions, as well as infectious diseases such as Malaria, TB, 
and HIV/AIDS. Since the 4Cs have achieved such a remarkable 
mortality reduction in these areas, we know it is technologically 
and medically feasible. The opportunity is here, the impact on 
health would be immense, and the cost not unreasonable if seen 
in the correct perspective. 
The Commission estimates that for 34 low-income countries, 
the extra cost will be about 23 billion US dollars annually from 
2016–2025, rising to around 27 billion US dollars annually 
from 2026–2035. For lower-middle-income countries the extra 
cost will be about 38 billion US dollars annually from 2016–
2025, rising to around 53 billion US dollars annually from 
2026–2035. These are large numbers, but what is remarkable 
is that the expected economic growth of middle-income 
countries will allow these countries to finance “convergence” 
entirely from domestic sources. The issue is political will and 
capacity to increase mobilization of domestic resources for 
health, to make inter-sectoral reallocations, and to improve 
technical efficiency (17). Low-income countries will require 
some external assistance, but they will be able to finance much 
of the incremental cost of achieving “convergence” themselves.
2. The returns to investing in health are even greater than originally 
estimated
Earlier macro-economic studies have explored and documented 
the national income gains from improved population health, 
not least increasing life expectancy. What is new in this report is 
that the Commission has taken what is called “full income” into 
account. Full income values not only economic productivity 
gains, but assigns also a monetary value to the intrinsic benefits 
of increased life expectancy. By combining demographic 
estimates of increasing life expectancy with the value of a 
statistics life (18), converted to the value of additional life years 
(8), the direct value of health improvements is captured in a 
way, and with results, that are truly noteworthy. For example, 
by looking only at “convergence” of under-five mortality, the 
increase in life expectancy could be up to 6.7 years for low-
income countries (19). This, by reflection, translates to a 
huge benefit measured in monetary terms. The Commission 
estimates that for every dollar invested in convergence-related 
interventions, the economic benefits are 9–20 times higher 
(8). That is, indeed, a remarkable return on investments. The 
message is clear: investing in interventions targeting infectious 
diseases, reproductive, maternal, neonatal, and child health 
conditions is not only cost-saving in the long run; it is also a 
very good investment. 
3. Fiscal policies and well-designed interventions can dramatically 
curb non-communicable diseases and injuries
The commission also looked at emerging chronic diseases and 
injuries. They propose a package of essential interventions 
consisting of cost-effective clinical interventions for NCDs and 
injuries, as well as powerful public health interventions such 
as increasing taxes on tobacco and alcohol (in countries where 
this has not been done) and reducing subsidies on items such as 
fossil fuels, which produce air pollutants that cause NCDs. For 
example, a 50% tax on tobacco could prevent 20 million deaths 
in China and generate 20 billion US dollars additional revenue 
annually.
4. Progressive universalism is an efficient way to achieve health 
and financial protection
From my perspective, the most remarkable conclusion, from 
this commission of economists and global health experts, is 
that “progressive universalism”—a term coined by Davidson 
Gwatkin and defined as a pro-poor pathway toward Universal 
Health Coverage (UHC) (20)—is an efficient way to achieve 
health and financial protection. The first pathway towards 
UHC that they recommend, and which I support, makes the 
“convergence interventions” the key. UHC should first protect 
everyone “by covering essential healthcare interventions 
to achieve convergence and tackle NCDs and injuries. This 
pathway would directly benefit the poor, because they are 
disproportionately affected by these problems” (8). Later, and 
in addition, a broader package funded through a wider range of 
financing mechanisms can be offered.
Conclusion
In summary, there are grounds for optimism in global health. 
Low- and middle-income countries can:
1. Aim for convergence in mortality and life expectancy 
with the 4Cs, the best-performing countries, within a 
generation.
2. Define and scale up essential services targeting infectious 
diseases, reproductive, maternal, neonatal, and child 
health conditions, and expand the range of services 
targeting NCDs and injuries.
3. Merge the idea of convergence interventions and the goal 
of progressive realization of universal health coverage. 
Essential interventions are good investments, they are the 
first important step on the path to UHC, and they will 
improve both health and provide financial protection. 
4. Increase revenue for health from economic growth, 
increased mobilization of domestic resources, inter-
sectoral reallocations and efficiency gains. For the poorest 
countries, external resources are needed. 
5. Justify this use of resources with reference to the fact that 
for every dollar invested in essential services aiming at 
“convergence”, the economic benefits are 9–20 times higher.
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Now that we have a better idea of what to do, and why, the 
next step is to understand better how. The challenge remains: 
Massive health inequalities still exist across countries. The vast 
majority of people who die from preventable deaths caused by 
infectious diseases or maternal and child health conditions live 
in low- and lower-middle income countries. A convergence is 
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